Literature DB >> 2524278

Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses.

J L Grun1, P H Maurer.   

Abstract

Mice were immunized with either poly(Glu, Arg, Ala) or poly(Glu, Lys, Phe) contained in two different adjuvant preparations, alum (A1K(SO4)2) or complete Freund's adjuvant (CFA), and in vitro antigen-driven proliferative responses of lymph node cells were assayed 4-16 days later. After immunization with antigens on alum, endogenous interleukin 1 (IL-1) as well as interleukin 4 (IL-4) production was required for the proliferation of the elicited T cells as inclusion of either polyclonal goat anti-mouse IL-1 alpha or monoclonal anti-mouse IL-4 (11B11) in the cultures inhibited proliferative responses to antigen. In contrast, proliferative responses of cells elicited by antigen in CFA were not inhibited by either anti-IL-1 or anti-IL-4. Monoclonal antimouse CD4 (GK 1.5) inhibited proliferative responses regardless of which adjuvant was used to elicit antigen-reactive cells. These data indicated that phenotypically different subpopulations of CD4+ cells were elicited by the same antigen administered in different adjuvant preparations, Th2-like cells after immunization with polymers on alum and Th1-like cells after immunization with antigens in CFA. An examination of the isotypes of polymer-specific antibodies present in the sera of immunized mice also supported this conclusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524278     DOI: 10.1016/0008-8749(89)90011-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  78 in total

Review 1.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 4.  Vaccines targeting drugs of abuse: is the glass half-empty or half-full?

Authors:  Kim D Janda; Jennifer B Treweek
Journal:  Nat Rev Immunol       Date:  2011-12-16       Impact factor: 53.106

5.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

6.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin.

Authors:  J M Brewer; J Alexander
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

Review 8.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

9.  The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies.

Authors:  J M Brewer; J Richmond; J Alexander
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.

Authors:  Brandon Feinen; Nikolai Petrovsky; Anita Verma; Tod J Merkel
Journal:  Clin Vaccine Immunol       Date:  2014-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.